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Lafora disease (LD), an inherited and fatal neurodegenerative disorder, is characterized by increased cellular glycogen content
and the formation of abnormally branched glycogen inclusions, called Lafora bodies, in the affected tissues, including neurons.
Therefore, laforin phosphatase and malin ubiquitin E3 ligase, the two proteins that are defective in LD, are thought to regulate
glycogen synthesis through an unknown mechanism, the defects in which are likely to underlie some of the symptoms of LD. We
show here that laforin’s subcellular localization is dependent on the cellular glycogen content and that the stability of laforin is
determined by the cellular ATP level, the activity of 5=-AMP-activated protein kinase, and the affinity of malin toward laforin. By
using cell and animal models, we further show that the laforin-malin complex regulates cellular glucose uptake by modulating
the subcellular localization of glucose transporters; loss of malin or laforin resulted in an increased abundance of glucose trans-
porters in the plasma membrane and therefore excessive glucose uptake. Loss of laforin or malin, however, did not affect glyco-
gen catabolism. Thus, the excessive cellular glucose level appears to be the primary trigger for the abnormally higher levels of
cellular glycogen seen in LD.
Glucose is an essential metabolite in living systems. However,the regulatory roles of glucose in cellular physiological path-
ways and themechanisms bywhich cells respond to changes in the
intracellular levels of glucose are not fully understood (26). Dys-
regulation in these processes is thought to underlie the pathology
of a few disorders that are associated with cytoplasmic glycogen
inclusions (50). One such disorder is Lafora disease (LD), a heri-
table and fatal neurodegenerative disorder characterized by pro-
gressive myoclonus epilepsy and other neurological deficits, in-
cluding ataxia and dementia (17, 41). A hallmark of LD is the
presence of Lafora bodies—insoluble and abnormally branched
intracellular glycogen inclusions called polyglucosan—in neu-
rons, muscle, liver, and other tissues (16, 17, 51, 52). LD is caused
by defects in the gene EPM2A, which encodes a dual-specificity
protein phosphatase named laforin, or the NHLRC1 gene, which
encodes an E3 ubiquitin ligase named malin (6, 15, 20, 32). Lafo-
rin harbors a carbohydrate-binding domain (CBD) that binds to
glycogen and Lafora bodies, both in vitro and in vivo (5, 18, 49).
Thus, a role for laforin in carbohydrate metabolism and in the
disposition of Lafora bodies was proposed (5, 18, 49). Besides
Lafora bodies, glycogen content has also been found at higher
levels in animals that were deficient for laforin or malin (11, 43).
Intriguingly, the glycogen reserve in LD animal models shows a
higher phosphate content (11, 43), and laforin has been shown to
dephosphorylate glycogen (43, 44). A recent report suggested that
glycogen phosphorylation possibly represents an error in a cata-
lytic step in glycogen synthesis and that its removal by laforin
could be a damage control mechanism (45). Since laforin and
malin are known to function as a complex (14, 19, 39, 46), it has
been proposed that laforin and malin, as nonredundant partners,
regulate multiple steps in glycogen metabolism (14, 43, 46, 48).
However, whether the laforin-malin complex regulates glycogen-
esis or glycogenolysis, or both of these processes, is yet to be re-
solved. For example, a role for laforin and malin in regulating the
cellular level of glycogen synthase (GS) (48) and R5/PTG (subunit
of protein phosphate 1) has been proposed (14, 46), but the cel-
lular levels (and activities) of GS and R5/PTG were found to be
unaltered in laforin- and malin-deficient mouse models (11, 44).
Thus, the specific pathway through which the laforin-malin com-
plex is able to regulate glycogen metabolic process is yet to be
unequivocally established. We show here that laforin could be a
glucose sensor, and its subcellular localization and stability are
determined by the intracellular level of glucose metabolites. We
further show that laforin and malin negatively regulate glucose
uptake by modulating the subcellular localization of glucose
transporters and that the loss of laforin or malin results in an
excessive buildup of glycogen, as seen in LD.
MATERIALS AND METHODS
Cell culture transfections and animal models. All experiments were car-
ried out in COS-7 cells unless otherwise stated. COS-7, Neuro2a, HepG2,
HEK293T, and HeLa cells were obtained from the National Centre for
Cell Sciences (India) and were grown in Dulbecco’s modified Eagle’s me-
dium (DMEM) with 25 mM glucose and 10% (vol/vol) fetal calf serum.
For glucose starvation, cells were grown in DMEMwithout glucose but in
the presence of serum. Cell were transfected using Lipofectamine 2000
(Invitrogen Inc.) or the Polyfect reagent (Qiagen India) as recommended
by the manufacturer. Muscle tissues of laforin-deficient mice and their
wild-type littermates (16) were obtained from Kazuhiro Yamakawa
(RIKEN Brain Science Institute, Japan). For the starvation studies, adult
mice (Swiss albino) were used.
Expression constructs and chemicals. The mammalian expression
constructs that code for the wild-type or the mutant forms of laforin and
malin have been described (19, 33, 36). The shRNA knockdown con-
structs (RNA interference [RNAi]) for laforin, malin, and the control
RNAi vector were purchased from Open Biosystems USA and have been
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validated in our previous studies (19, 36). The constructs that code for the
wild-type and the dominant negative form of 5=-AMP-activated protein
kinase (AMPK)were obtained fromAddgene (plasmid IDnumbers 15991
and 15992, respectively). Green fluorescent protein (GFP)-tagged expres-
sion constructs for Glut1 and Glut3 were generously provided by Juan P.
Bolanos (Universitario de Salamanca, Spain). All chemicals were pur-
chased from Sigma-Aldrich Pvt. Ltd. (India) unless stated otherwise.
Glucose deprivation. For glucose deprivation, the cells, after transfec-
tion with the desired mammalian expression constructs wherever appli-
cable, were first allowed to grow in glucose (25 mM) containing DMEM
for at least 15 h and then shifted toDMEMwithout glucose for the next 12
or 24 h, as indicated below.
Pharmacological treatments. Cells were treated with the following
pharmacological agents: L-glucose (25mM),mannitol (25mM), 2-deoxy-
glucose (2-DOG; 25 mM), 3-O-methyl glucose (3-OMG; 25 mM), cyclo-
heximide (1 mg/ml), cytochalasin B (20 g/ml), sodium azide (10 mM),
mannoheptulose (20 mM), forskolin (100 M), glucosamine (10 mM),
diazo-oxo-norleucine (DON; 40 M), benzyl-2-acetamido-2-deoxy--
D-galactopyranoside (BADGP; 10mM),MG132 (20M),metformin (10
mM), compound C (40 M), and 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-
4-yl) amino]-2-deoxy-D-glucose (2-NBDG; 50 M). The duration of
treatment ranged from 12 to 24 h.
Immunostaining and antibodies. Cells, grown on a gelatin-coated
sterile glass coverslip, were processed for immunofluorescence micros-
copy as described previously (19, 33). Briefly, cells were fixed with 4%
paraformaldehyde, permeabilized with Triton X-100 (0.05%) and subse-
quently incubated with primary and secondary antibodies as per the sup-
pliers’ instructions. For staining the nuclei, cells were treated with 10 M
4=,6-diamidino-2-phenylindole (DAPI) for 5 min. Immunofluorescence
images were captured using a high-end fluorescence microscope (Nikon
Eclipse 80i; 40 oil objective; Nikon, Japan) andwere processed using the
Media Cybernetics ImagePro Express image analysis and deconvolution
software. The following antibodies were used in the present study: anti-
Myc and anti-GFP (Roche India); anti-AMPK, anticaveolin, and anti-
flotillin 2 (Cell Signaling Technology); anti-Glut1, anti-Glut3, and
anti-Glut4 (Millipore India); anti--O-linked N-acetylglucosamine and
antitubulin (Sigma-Aldrich India Pvt. Ltd.); anti-transferrin receptor
antibody (BD Transduction Laboratories). Anti-laforin antibody was de-
scribed in our previous study (36). Antiglycogen antibody was a generous
gift from Otto Baba (Tokyo Medical and Dental University, Japan). Sec-
ondary antibodies were obtained from Jackson ImmunoResearch Inc.
Cell counting. Laforin’s nuclear localization was scored by viewing
cells with a fluorescence microscope in a blinded manner. For each con-
dition/treatment, at least 300 cells were counted, and the data are pre-
sented as the percentage of cells having nuclear localization of protein.
Pulldown assay. In vivo protein-protein interactions were estab-
lished by using Ni-affinity resins as described previously (13, 19).
Briefly, the lysate of cells that coexpressed His-tagged malin and GFP-
tagged laforin was incubated with Ni-affinity resin (Sigma-Aldrich)
for 2 h at 4°C and processed according to the manufacturer’s instruc-
tions. The whole-cell lysate and pulldown fraction were detected by
immunoblotting using specific antibodies.
Immunoblotting. For immunoblotting, protein samples were sepa-
rated through SDS-PAGE gels and transferred onto a nitrocellulose paper
(MDI, India). After blocking with 5% nonfat dry milk powder, the mem-
branes were processed for sequential incubations with primary and sec-
ondary antibodies. Immunoreactive proteins on the filters were visualized
using a chemiluminscence detection kit (SuperSignalWest PICO; Pierce).
Signal intensities of the blots were measured using the NIH ImageJ soft-
ware.
AMPK activity assay. AMPK activity wasmeasured by using a peptide
substrate (SAMS) purchased from Upstate, Millipore, as previously de-
scribed (10, 38). Briefly, the cell were lysed by sonication in an ice-cold
lysis buffer at 4°C (50 mM Tris-HCl [pH 7.4], 250 mM mannitol, 1 mM
sodium pyrophosphate, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol
[DTT], 0.1 mM benzamidine, 0.1 mM phenylmethylsulfonyl fluoride
[PMSF], 5 g/ml soybean trypsin inhibitor, and 1% Triton X-100) sup-
plemented with phosphatase (Roche Diagnostics) as well as protease in-
hibitor cocktail (Sigma-Aldrich India Pvt. Ltd.). The lysate was centri-
fuged (14,000 g for 5 min at 4°C), and the supernatant was used for the
kinase assay. For the kinase assay, an equal amount of protein (50g) was
added to a reaction mixture containing 5 l assay buffer (62.5 mM Na-
HEPES [pH 7.0], 62.5 mM NaF, 62.5 mM NaCl, 1.25 mM EDTA, 1.25
mMEGTA, 1.25mMsodiumpyrophosphate, 0.1mMPMSF, 1mMDTT,
0.1 mM benzamidine, 5 g/ml soybean trypsin inhibitor), 5 l of 1 mM
SAMS peptide, and 5 l of 1 mM AMP. Finally, [-32]ATP (300 to 500
cpm/pmol) was added along with 5 mM MgCl2, and the reaction was
carried out at 37°C for 10 min. Twenty-microliter aliquots were spotted
on a phophocellulose paper (P81;Whatman) andwashed 4 times with 1%
H3PO4 (500 ml) and once with acetone, then air dried and counted in a
scintillation counter (PerkinElmer Life Sciences). The AMPK activity is
reported as pmol/min/mg of protein.
Glucose uptake assay. A glucose uptake assay was performed essen-
tially as described earlier (34). Transfected cells at 36 h posttransfection
were incubated with Krebs-Ringer-HEPES (KRH) buffer for 1 to 2 h, and
then 50M2-NBDG (Invitrogen) was added for 10min at 37°C. The cells
were then washed and lysed by sonication, and the lysate was centrifuged
at 12,000 g for 5 min at 4°C. A small aliquot of the lysate was saved for
protein estimation (Bradford method). The fluorescence intensity of the
remaining cell lysate was measured using a fluorescence spectrometer (LS
55; Perkin-Elmer). As a control, the fluorescence levels of the lysate from
cells treated with an inhibitor of glucose uptake, cytochalasin B (10 M),
were measured. Fluorescence values were normalized based on protein
estimation data and are presented as the fold change.
Plasma membrane fractionation. Plasma membrane fractionation
from cultured cells was performed essentially as described elsewhere (2).
At 36 h posttransfection, cells were first washed twice with phosphate-
buffered saline and then scraped into detergent-free cell lysis buffer (10
mM Tris [pH 7.5], 137 mMNaCl, 2 mM phenylmethylsulfonyl fluoride)
and a phosphatase and protease inhibitor cocktail. Cells were left on ice
for 10 min and then sonicated to disrupt plasma membranes. Cell lysate
was cleared first by low-speed centrifugation as 12,000 g for 5 min, and
then the cleared lysate was separated by ultracentrifugation at 100,000 g
(Sorvall MTX 150 microultracentrifuge; rotor S55-S) for 1 h. Superna-
tants were saved, and pellets were washed twice with lysis buffer and then
resuspended in an equal amount of lysis buffer containing 1% Triton
X-100.
For fractionation of the plasmamembrane frommouse soleus skeletal
muscle tissue, the protocol of Dombrowski et al. (12) was followed.
Briefly, 500 mg of muscle tissue was homogenized in buffer A (10 mM
sodium bicarbonate [pH 7.0], 0.25mM sucrose, 5 mM sodium azide, and
100 M phenylmethylsulfonyl fluoride). The homogenate was centri-
fuged at 1,300  g for 10 min, supernatant was saved, and the resulting
pellet was homogenized in buffer A. The homogenate was centrifuged at
1,300  g for 10 min. The supernatant fractions from both steps were
combined and centrifuged at 9,000  g for 10 min, and the resulting
supernatant was centrifuged at 190,000  g for 1 h. The pellet fraction
from this step was dissolved in sucrose-free buffer A and loaded on top of
discontinuous sucrose density gradients (25, 32, and 35% [wt/wt]). The
gradient was centrifuged at 150,000  g for 16 h, and the plasma mem-
brane fractions were collected from the top 25%of the gradient, diluted in
buffer A, and centrifuged at 190,000  g for 1 h. The final pellet was
resuspended in buffer A. Samples were resolved by SDS-PAGE and im-
munoblotted as described above.
Proteasome activity assay. Proteasome activity in cell extract was
quantified using a fluorogenic proteasome substrate, Suc-Leu-Leu-Val-
Tyr-AMC (Calbiochem), as per the manufacturer’s instructions. Briefly,
10 g of protein was incubated with the proteasome substrate in assay
buffer for 2 h at 50°C, and fluorescence intensity was measured using a
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spectrofluorometer (excitation, 380 nm; emission, 460 nm). Assays were
performed in triplicates.
Glycogen estimation. Cellular glycogen content was estimated as de-
scribed previously (42). The cells were suspended in 100 l of ice-cold
30% KOH and heated at 100°C for 20 min. A small aliquot of the sample
was saved for protein estimation, and the rest was spotted onto a filter
paper (Whatman 31-ET CHR). The paper was washed in ice-cold 66%
ethanol for 10 min, followed by two washes in the same solution at
room temperature, dried overnight at 37°C, and then incubated in
amyloglucosidase (0.5 mg/ml in 0.02 M sodium acetate [pH 4.8]) for 2
h at 37°C. The released glucose was measured by using a glucose esti-
mation kit (ERBA Diagnostic Mannheim Gmbh Ltd.), and the quan-
tity of glycogen is presented as the amount of released glucose per mg
of total protein.
Statistical analysis. Data were analyzed by a two-tailed, unpaired Stu-
dent’s t test using GraphPad software. Differences were considered signif-
icant at a P level of0.05. Experiments were performed at least in tripli-
cates, and scoring of cells (200 cells per set) was done in a blinded
manner.
RESULTS
Subcellular localization of laforin, but not that of malin, is reg-
ulated by the extracellular glucose level. To explore whether glu-
cose availability modulates the subcellular localization of laforin
and malin, GFP-tagged laforin and malin were transiently ex-
pressed in COS-7 cells, and their subcellular localizations were
evaluated by growing the cells for 24 h in a medium with glucose
(25 mM) or no glucose. Laforin was exclusively localized in the
cytoplasm of the cells grown in glucose-rich medium, while a sig-
nificant population of cells grown in the glucose-free medium
showed laforin in the nuclear compartment (Fig. 1A and B). The
glucose starvation-induced nuclear translocation of laforin was
found to be independent of the fusion tags used and the cell lines
employed (data not shown), and it was not induced by serum
starvation (Fig. 1A). The glucose-dependent localization of laforin
was also noted in an earlier study (7). Malin did not show any
difference in the subcellular localizationwhen the cells weremain-
tained in the glucose-free medium (Fig. 1C). The nuclear translo-
cation of laforin was further confirmed by fractionating the cellu-
lar components into nuclear and cytoplasmic fractions; we
detected laforin in the nuclear fraction of the glucose-starved cells
(Fig. 1D). Similar observations were made when endogenous la-
forin was tested in the fractionated samples using an anti-laforin
antibody (Fig. 1D). The antilaforin antibody, whose specificity
was established previously (36, 39), did not work in the immuno-
fluorescence staining.
We next checkedwhether the presence ofmalinmodulated the
glucose-dependent nuclear translocation of laforin. Neither the
loss of malin nor its coexpression prevented laforin’s nuclear
translocation when the cells were grown in the glucose-free me-
dium (Fig. 1E). We also checked whether the nuclear transloca-
tion of laforin was a reversible process. For this, cells expressing
FIG 1 Subcellular localization of laforin is regulated by the extracellular glucose level. (A) Representative images showing the subcellular localization of
GFP-tagged laforin in cells grown in the presence/absence of glucose or serum, as indicated. (B) The percentage of cells showing nuclear localization of laforin
(as shown in panel A) when grown in the presence or absence of glucose. (C) Representative images showing subcellular localization GFP-tagged malin in cells
grown in the presence/absence of glucose. (D) The cytoplasmic (C) and nuclear (N) fractions of cells grown in the presence () or absence (-) of glucose were
immunoblotted to show enrichment of GFP-tagged laforin (upper panel) or endogenous laforin (lower panel) in the nuclear compartment. (E) The percentage
of cells with nuclear localization of laforin when coexpressed with the indicated RNAi vector. The gel on the right shows RNAi-mediated reduction in the level
of malin RNA, as detected by a semiquantitative PCR. Amplification of 7SK RNA served as a control. (F) Cells expressing GFP-tagged laforin were grown in
glucose-free medium for 12 h and were then transferred to medium without glucose (bar 1), glucose-free medium with only cycloheximide added (bar 2), or
medium with cycloheximide and glucose added (bar 3). The percentage of cells showing nuclear localization was scored at the end of 12 h of incubation. Bars in
panels A and C, 10 m. , P 0.0005.
Singh et al.
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GFP-laforin were first grown in glucose-freemedium for 12 h and
then transferred to amedium containing either cycloheximide (at
1 mg/ml; a translational blocker) and glucose (25 mM) or a
glucose-free medium containing only cycloheximide. There was a
significant reduction in the number of cells in which laforin local-
ized in the nucleus in the set that was transferred to the medium
containing glucose compared to the set that was maintained in
glucose-free medium (Fig. 1F). Thus, the glucose-dependent nu-
clear translocation of laforin appears to be a reversible process.
The nucleus-to-cytoplasmmovement of laforin is independent of
CRM1/exportin 1 protein, as leptomycin B treatment did not in-
hibit the translocation (data not shown).
The intracellular glycogen level regulates laforin’s subcellu-
lar localization. To establish the mechanism by which glucose is
able to modulate the subcellular localization of laforin, we first
checked whether glucose uptake is required for the cytoplasmic
retention of laforin. For this, cells transiently expressing laforin
were incubated in a medium containing L-glucose (an analog of
D-glucose that does not enter the cell) or in glucose-containing
medium supplemented with cytochalasin B (an inhibitor of glu-
cose transport) for 24 h. Both these treatments resulted in the
nuclear translocation of laforin in a significant number of cells
(Fig. 2A), suggesting that glucose entry into the cell is a prerequi-
site for the retention of laforin in the cytoplasm. Supplementing
the glucose-free medium with D-mannitol (24 h) did not prevent
laforin from translocating into the nucleus (Fig. 2A), suggesting
that laforin’s nuclear translocation is not due to the osmolarity
difference.
Glucose, upon entry into the cell, gets converted into glucose-
6-phophate via phosphorylation, and this in turn is routed into
several metabolic pathways. We were therefore interested in
checkingwhether phosphorylatable glucose could be the signal for
laforin’s retention in the cytoplasm. For this, cells transiently ex-
pressing laforin were maintained in medium containing either
3-OMG (25 mM; a nonphosphorylated glucose analogue) or
2-DOG(25mM; a phosphorylated glucose analogue) for 24 h, and
the localization of laforin was scored. As shown in Fig. 2B, 2-DOG
but not 3-OMG was able to retain laforin in the cytoplasm. To
confirm further whether phosphorylation of glucose is essential
for laforin to stay within the cytoplasm, the laforin-expressing
cells were treated with mannoheptulose (20 mM; 24 h), a potent
and specific inhibitor of hexokinase activity (9). Addition ofman-
noheptulose did not alter laforin’s translocation into the nucleus,
suggesting that the observed effect of 2-DOG is due to its physio-
logical role, which is independent from its phosphorylation status
(Fig. 2B). Taken together, these results suggest that laforin’s sub-
FIG2 The intracellular glycogen level regulates laforin’s subcellular localization.Nuclear localization of laforinwhen cells were incubated inmedium containing
glucose, D-mannitol, L-glucose, or cytochalasin B (CytoB) (A) or with glucose, 3-OMG, 2-DOG, mannoheptulose (manhept), sodium azide (NaN3), or no
addition (B) in the presence/absence of glucose is shown. (C) Bar diagram showing ATP levels in cells treated with glucosamine (Glumn), 2-DOG, or sodium
azide in the presence/absence of glucose (Glu), as indicated. (D) Representative images showing the subcellular localization of GFP-tagged laforin in cells treated
with forskolin (FSK) in the presence of glucose (top panel) or with glucosamine (Glumn) in the absence of glucose (lower panel). Bar, 10 m. (E) Bar diagram
showing the glycogen content in cells transiently expressing GFP-tagged laforin after various treatments as indicated (top panel) or the nuclear localization of
laforin (lower panel). (F) Bar diagram showing nuclear localization of laforin (upper panel) or the level of glycosylated protein (immunoblotwith anti-O-GlcNAc
antibody; lower panel) in cells treated with glucose, glucosamine, or DON. (G) Nuclear localization of laforin (upper panel) or glycogen content (lower panel)
in cells treated with glucose or glucose analogues (DOG or OMG). , P 0.0005; , P 0.005.
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cellular localization is independent of glucose phosphorylation
(see below).
Phosphorylated glucose has several metabolic fates within the
cell, and we wanted to check which of these pathways could regu-
late laforin’s nuclear localization. Addition of sodium azide (for
12 h), an established inhibitor of oxidative phosphorylation and
ATP production (1), did not alter laforin’s subcellular localization
(Fig. 2B), although it significantly reduced the cellular ATP level,
which was comparable to the condition in which cells were de-
prived of glucose (Fig. 2C). Consistentwith a previous report (53),
a reduced ATP level was also observed when the cells were treated
with 2-DOG (Fig. 2C), suggesting that laforin’s translocation into
the nucleus is not dependent on cellular ATP levels. Next, we
checked whether the cellular glycogen level modulated laforin’s
nuclear localization. For this, laforin-expressing cells were treated
with forskolin (12 h), a drug that promotes glycogen degradation
(3, 8). In a parallel experiment, transfected cells were maintained
in glucose-free medium supplemented with glucosamine (12 h).
Glucosamine is a key metabolite of the hexosamine biosynthetic
pathway (HBP), and supplementing the glucose-free medium
with glucosamine is known to result in normal levels of glycogen,
even under glucose deprivation conditions in vitro (30). Glucosa-
mine treatment led to the retention of laforin in the cytoplasmic
compartment in a majority of cells, even when they were main-
tained in glucose-free medium (Fig. 2D and E). On the other
hand, addition of forskolin resulted in laforin translocating to the
nucleus even when the cells were grown in glucose-containing
medium (Fig. 2D and E). Thus, a higher glycogen level appears to
restrict laforin’s localization to the cytoplasmic portion (Fig. 2E).
Since glucosamine and forskolin are also known to modulate the
glycosylation of cellular proteins via the HBP (21), a glucose de-
pendent process, we also checked whether protein glycosylation
could play a role in laforin’s nuclear translocation. For this, COS-7
cells transiently expressing laforin were treated (24 h) with DON
or BADGP, two potent inhibitors of the glycosylation process
(25). While DON did reduce glycosylation of cellular proteins, it
did not induce nuclear translocation of laforin (Fig. 2F). A similar
observation was made when BADGP was used (data not shown),
suggesting that glycosylationmay not play amajor role in laforin’s
nuclear translocation. We finally checked whether the observed
effects of the nonmetabolizable glucose analogues 2-DOG and
3-OMG on laforin’s subcellular localization could be due to their
effects on cellular glycogen content. Treatment with 2-DOG, but
not 3-OMG, indeed led to increased glycogen content, even when
cells were deprived of normal glucose, and this increased glycogen
content correlated with laforin localization within the cytoplasm
(Fig. 2G). Taken together, these results suggest that cellular glyco-
gen is a major determinant for laforin’s subcellular localization.
Laforin’s subcellular localization is dependent on its ability
to bind to glycogen. Laforin is known to bind to a glycogen com-
plex through its amino-terminal CBD (5, 18, 49), and some LD-
associated mutations affect laforin’s ability to bind to glycogen
and/or its subcellular localization (41). We were therefore inter-
ested in whether laforin’s glycogen-binding property is critical for
its glycogen-dependent subcellular localization. For this, we se-
lected four missense mutants of laforin: two affecting the CBD
(E28L and W32G) and two affecting the phosphatase domain
(C266S and G279S) (Fig. 3A). Intriguingly, laforin mutants E28L,
C266S, and G279S (all three are inactive phosphatases [41]) were
able to translocate to the nucleus upon glucose deprivation (Fig.
3B andC). On the other hand,mutantW32G, which is an inactive
phosphatase and does not bind to glycogen in vitro (14, 18, 27, 49),
was localized predominantly in the nucleus regardless of glucose
availability (Fig. 3B and C). Therefore, the carbohydrate-binding
ability, and not the phosphatase activity, could be the critical fac-
tor that determines laforin’s subcellular localization.
Intracellular glucose availability regulates malin-dependent
degradation of laforin. We consistently found the cellular level of
transiently expressed laforin to be lower when cells where grown
in glucose-free medium. Since laforin is one of the substrates of
the malin E3 ubiquitin ligase, we tested whether intracellular glu-
cose availability modulated laforin’s affinity toward malin and its
degradation. There was a significant reduction in the cellular level
of laforin upon glucose deprivation (24 h) (Fig. 4A andB). Endog-
enous laforin was also found at reduced levels in the livers mice
that were starved for 24 h compared to mice fed ad libitum (Fig.
4C). An increase in laforin level was observed when glucose-
starved cells were treated with the proteasomal blocker MG132
(for the last 16 h of the 24-h glucose deprivation) (Fig. 4D and E),
suggesting that laforin is degraded through the proteasome when
cells are starved of glucose. Similarly, the laforin level was lower in
glucose-deprived cells that coexpressed wild-type malin than in
the control set, which coexpressed the catalytically inactive mu-
tant malin C26S (Fig. 4F), and the laforin level increased when
endogenous malin was partially knocked down (Fig. 4G). Malin
enhanced laforin degradation during glucose deprivation at a
higher rate than under glucose-fed conditions (Fig. 4H). Thus,
malin appears to promote the degradation of laforin in a glucose-
dependent manner.
Since laforin’s nuclear localization is dependent on the cellular
glycogen content rather than on the free glucose level, we next
tested whether laforin’s stability was also dependent on cellular
glycogen content. For this, cells were treated with either glucosa-
mine or forskolin in the absence or presence of glucose, respec-
tively (24 h), and the cellular levels of endogenous or transiently
FIG 3 Subcellular localization of laforin mutants. (A) Schematic diagram of
the domain organization of laforin and the positions of missense mutations
(CBD and dual-specificity phosphatase domain [DSPD]). (B) Representative
images of the subcellular localization of laforin mutants in the presence/ab-
sence of glucose. Bar, 10 m. (C) Bar diagram showing nuclear localization of
laforin mutants in the presence/absence of glucose. , P 0.0005.
Singh et al.
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expressed laforin were evaluated. Surprisingly, glucosamine treat-
ment led to a further reduction in the level of laforin (Fig. 4I and
J), although the cellular glycogen content was comparable to that
of glucose-fed cells (Fig. 2E). On the other hand, forskolin treat-
ment did not significantly alter the laforin level (Fig. 4I and J),
although the cellular glycogen content was significantly lower
than in glucose-fed cells (Fig. 2E). These results strongly suggest
that cellular glucose availability and not the glycogen content de-
termines laforin’s stability.
AMPK activity is required for degradation of laforin under
glucose deprivation. AMPK is an energy sensor kinase, since a
drop in the intracellular ATP level (for example, during glucose
deprivation) rapidly activates AMPK (22). Since the laforin-malin
interaction is dependent on AMPK (37, 42), we next tested
whether the glucose-dependent degradation of laforin by malin
could bemediated byAMPK.Glucose deprivation or glucosamine
treatment led to a significant increase in AMPK activity without a
change in its level (Fig. 5A). Glucosamine treatment is known to
enhance the AMPK activity by reducing the cellular ATP level (24,
29), and similar observations were made in the present study as
well (Fig. 2C), suggesting that the increased AMPK activity could
be one of the key regulators of laforin’s stability during glucose
deprivation as well as during glucosamine treatment. Indeed, we
found that coexpression of a dominant negative form of AMPK
(DN-AMPK) in glucose-free medium resulted in an increase in
the cellular level of laforin (Fig. 5B). We next checked whether
AMPK regulates the affinity between laforin andmalin when cells
are deprived of glucose. For this, laforin was expressed with a
His-tagged, catalytically inactive malin mutant (C26S), and the
cells were either treated with an inhibitor for AMPK (compound
C; 12 h) or with the vehicle (dimethyl sulfoxide; 12 h), and the
His-tagged malin was pulled down using Ni-affinity resins. The
C26S mutant malin was used in the pulldown assay, because
the signal intensity of the pulled-down product would represent
the amount of protein available for the interaction and not the
amount that escaped malin-mediated degradation (13). The mu-
tant malin exhibited a robust interaction with laforin when the
cells were deprived of glucose, and this interaction was compro-
mised when the cells were treated with the AMPK inhibitor (Fig.
5C). However, AMPK blockade (treatment with compound C or
coexpression of AMPK-DN) did not prevent laforin’s nuclear
translocation when cells were deprived of glucose (Fig. 5A, D, and
E). Thus, AMPK appears to regulate the stability and not the sub-
cellular localization of laforin.
Since overexpression of AMPK-DN resulted in an increase in
the level of laforin in cells that were starved of glucose, we next
checked whether overexpression of AMPK or enhancement of its
activity in the presence of glucose would bring down the cellular
level of laforin. Intriguingly, activation of AMPK, either by its
overexpression or by treating the cells withmetformin, a drug that
activates AMPK independently of cellular ATP/AMP levels (23),
resulted in a significant increase in the level of laforin in cells that
were grown in glucose-containing medium (Fig. 6A). This could
possibly mean that activation of AMPK is necessary but not suffi-
cient to degrade laforin and that AMPK might require other fac-
tors for its action on laforin. The energy-sensing property of
AMPK raises the possibility that the cellular ATP level could be a
cofactor that contributes to laforin’s stability, since the ATP level
FIG 4 Intracellular glucose availability regulates malin-dependent degradation of laforin. (A and B) Lysates of cells grown in the presence or absence of glucose
were immunoblotted with an antibody to detect endogenous laforin, tubulin or GRP75 (A) or transiently expressed laforin (B). (C) Endogenous laforin level in
liver tissue lysates (70g of protein/lane) frommice thatwere either fed ad libitum (F) or starved for 24 h (S). (D andE)Cellular levels of the overexpressed laforin
(D) or its endogenous form (E) in cells that were grown in the presence/absence of glucose and/orMG132, as indicated. (F andG)Cells coexpressingGFP-tagged
laforin with wild-type malin or its mutant C26S (F) or a knockdown construct for malin (G) were evaluated by immunoblotting. (H) Cells expressing the
indicated constructs in the presence or absence of glucose were processed for immunoblotting to establish the relative levels of GFP-tagged laforin. (I and J) Cells
were exposed to pharmacological agents as indicated, and the cell lysates were processed for immunoblotting to detect the level of transiently expressed
GFP-tagged laforin (I) or endogenous laforin (J).
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goes down when cells are deprived of glucose. To test this possi-
bility, cells that transiently expressed laforin were treated with
sodium azide (12 h), a compound that reduces the cellular ATP
content even in the presence of glucose (Fig. 2C), and the cellular
level of laforin was evaluated. Sodium azide treatment resulted in
a significant reduction in the cellular laforin level, even in the
presence of glucose (Fig. 6B). However, the same treatment did
not alter laforin’s subcellular localization (Fig. 2B), suggesting that
the cellular ATP level plays a critical role in determining laforin
stability in addition to regulating the activity of AMPK. We next
evaluated the subcellular distribution of laforin upon coexpres-
sion of AMPK or by treating the transfected cells with metformin
(24 h). Intriguingly, both conditions resulted in the recruitment of
laforin into perinuclear granule-like structures in transfected cells
(in 40% cells upon AMPK coexpression and in 72% cells
treated with metformin) that also stained positive for glycogen
(Fig. 6C and D). However, such a staining pattern was not ob-
served when cells were maintained in glucose-free medium (Fig.
6C, lower panel), suggesting that glucose deprivation may have
resulted in the utilization of the glycogen reserve, thereby abolish-
ing the granule-like staining pattern. Overexpression of AMPK is
known to localize this protein onto cytoplasmic glycogen granules
(35), suggesting that the activation of AMPK results in an increase
in intracellular glycogen content. Indeed, metformin-treated cells
grown in glucose-containing medium showed increased intracel-
lular glycogen content compared to untreated cells (Fig. 6E).
There was also a moderate yet significant reduction in protea-
somal activity upon metformin treatment (Fig. 6F, lower panel).
However, these perinuclear granules are unlikely to be “ag-
gresomes,” since coexpression of AMPK (DN or the wild-type)
did result in similar recruitment of laforin without compromising
proteasomal activity (Fig. 6F). Thus, sequestration of laforin to
glycogen particles upon AMPK activation in the presence of glu-
cose could be one of the reasons for its elevated levels in
metformin-treated cells. Nonetheless, the present results are com-
pelling enough to suggest that while the subcellular localization of
laforin is dependent on the cellular glycogen content, the stability
of laforin is dependent on the cellular ATP level and the AMPK
activity.
The laforin-malin complex regulates cellular glucose uptake
by modulating subcellular localization of glucose transporters.
Based on our observations that glycogen metabolites regulate the
stability and subcellular localization laforin and previous reports
on the role of the laforin-malin complex in glycogen metabolism,
we reasoned that the laforin-malin complex might regulate cellu-
lar glucose uptake, the first step of the glycogen metabolic path-
way. For testing this hypothesis, we used Neuro2a cells, as this cell
line is known to store much less glycogen (48), and therefore dif-
ferences in the glycogen level could be easily measured. The ex-
pression of laforin or malin was partially suppressed by the RNAi
approach, and cellular glucose uptake was measured using the
fluorescent D-glucose analogue 2-NBDG. Partial knockdown of
laforin or malin resulted in a significant increase in basal glucose
uptake compared to the control set (Fig. 7A). Similar observations
were made in COS-7 cells, although the difference was minimal
compared to that in Neuro2A cells (data not shown). To elucidate
the mechanism by which cells enhance glucose uptake upon the
loss of laforin or malin, we first evaluated the relative levels of
endogenous glucose transporters Glut1 and Glut3 in the mem-
brane fraction of COS-7 and Neuor2A cells. Glut3 is expressed
specifically in the neuronal cells, while Glut1 is expressed in most
tissues, although both transporters are involved in basal glucose
uptake (31). Loss of laforin or malin did not alter the cellular level
of either Glut 1 (COS-7 cells) or Glut3 (Neuro2A cells) (Fig. 7B).
FIG 5 AMPK activity is required for the degradation of laforin under glucose deprivation. (A) Bar diagram showing the fold difference in AMPK activity in cells
treatedwith the indicated compounds. The immunoblot (lower panel) shows AMPK levels in the cell lysates. (B) Cells expressing AMPK-DN and/or GFP-tagged
laforin weremaintained inmedium containing or deprived of glucose and processed for immunoblotting, as indicated. (C) Cells transfected with constructs that
code for GFP-tagged laforin and Myc/His-tagged mutant malin (C26S) were processed for a Ni affinity-based pulldown assay. The pulled-down (PD) and
whole-cell lysates (WCL) were immunoblotted with the indicated antibodies. (D) Bar diagram showing the effects of DN-AMPKon laforin nuclear localization
under glucose deprivation conditions. (E) Bar diagram showing the difference in AMPK activity (upper panel) or the frequency of cells with nuclear localization
of laforin (lower panel) when grown in the presence or absence of glucose or compound C, as indicated. , P 0.005; , P 0.05.
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However, their loss resulted in a significant increase in the level of
Glut1 and Glut3 in the plasma membrane fraction (Fig. 7B). No
such difference, however, was noted for the transferrin receptor, a
protein that also localizes in the plasma membrane, suggesting
that the difference in the signal intensity observed for Glut1 and
Glut3 is specific to these proteins and not due to the difference in
the protein content of the membrane fraction per se. The enrich-
ment of plasma membrane proteins in the fractionated samples
was established by probing fractions with antibodies for the trans-
ferrin receptor or flotillin 2 (Fig. 7C). The Glut1 and Glut4 pro-
teins were found to be enriched in the plasma membrane fraction
of the soleus skeletal muscle tissue of laforin-deficient mice (Fig.
7D), suggesting that such targeting may not be restricted to cell
lines. Thus, laforin and malin appear to negatively regulate the
targeting of glucose transporters to the plasma membrane, and
defects in this process could result in increased glucose uptake in
the absence of laforin or malin.
Glucose transporters are normally localized in the vesicular
compartments of the cytoplasm and are targeted to the plasma
membrane, allowing glucose import upon appropriate signaling
(4, 28). Therefore, we wanted to test whether laforin/malin regu-
late the intracellular trafficking of glucose transporters. For thiswe
chose Neuro2A cells, wherein the overexpressed Glut3 (but not
the endogenous form) resides primarily at the plasma membrane
(40). When Glut3 was coexpressed with laforin or malin, a signif-
icant amount of overexpressed Glut3 was retained in the cytoplas-
mic compartment in around 70%of the cells (data not shown). To
further validate this observation, we fractioned the plasma mem-
branes and evaluated the Glut3 by immunoblotting. While the
level of Glut3 in the whole-cell lysate did not show any change,
there was a significant reduction in the level of Glut3 in the plasma
membrane fraction of cells that coexpressed the wild-type form of
laforin ormalin compared to the sets that coexpressed the catalyt-
ically inactive mutant forms of laforin or malin (Fig. 7E and F).
Corroborating this observation, overexpression of wild-type lafo-
rin and malin, but not their mutants, significantly reduced the
cellular glucose uptake (Fig. 7G). Taken together, our results sug-
gest that laforin and malin are important for the cytoplasmic re-
tention of glucose transporters and that the functional loss of la-
forin ormalin results in the targeting of glucose transporters to the
plasma membrane and excessive glucose uptake.
Laforin and malin regulate glycogen synthesis but not its
breakdown. Since loss of laforin ormalin resulted in the excessive
uptake of glucose, we wanted to check whether loss of these pro-
teins and the plasma membrane localization of glucose trans-
porter would induce glycogen accumulation. For this, we selected
two distinct cell types: (i) Neuro2A, a cell line of neuronal origin
that stores a very small amount of glycogen, and (ii) COS-7, a
nonneuronal cell type that stores 100-fold-higher levels of gly-
cogen than Neuro2A cells (Fig. 8A). Transient knockdown of la-
forin or malin resulted in a significant increase in the intracellular
glycogen level in both Neuro2A and COS-7 cells (Fig. 8B). Cor-
roborating this observation, nearly 20% of the cells that were
transfected with the laforin or malin RNAi construct showed gly-
cogen granules when stained with an antibody against glycogen,
while the control set did not show any such staining (Fig. 8C). To
FIG 6 AMPK is necessary but not sufficient to degrade laforin. (A) Cells expressing laforin-GFP, wild-type AMPK (AMPK-WT), or AMPK-DNwere treated the
indicated compounds and processed for immunoblotting. (B) Cells expressing GFP-tagged laforin were grown in media containing the indicated compounds
and processed for immunoblotting. The signal intensities (laforin/tubulin ratio) weremeasured and plotted as a bar diagram to reveal the fold difference. (C and
D) Representative images of the subcellular localization of laforin and wild-type AMPK when coexpressed in COS-7 cells grown in the presence/absence of
glucose (C) or the recruitment of overexpressed laforin to the glycogen particle whenNeuro2A cells were grown in amedium containing glucose andmetformin
(GluMF) (D). Bar, 10m(C andD). (E) Bar diagram showing intracellular glycogen content inCOS-7 cells grown in the presence or absence of glucose and/or
metformin (MF). (F) Bar diagram (upper panel) showing nuclear localization of laforin in cells treated with metformin or when coexpressed with the wild-type
(WT)AMPKor itsDN form. The lower panel shows proteasome activity in the lysates of cells under various conditions. Cells treatedwithMG132 andmetformin
were transfected with an empty vector.  and , P 0.05 and 0.0005, respectively.
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further establish that the enhanced glycogen content was indeed
due to increased glucose uptake, we treated cells with an inhibitor
of glucose uptake (cytochalasin B) and measured their glycogen
content. The cellular glycogen contents of cells lacking laforin or
malin did not differ significantly from cells that were transfected
with control vector (Fig. 8D), suggesting that loss of laforin or
malin promotes intracellular glycogen accumulation via increased
glucose uptake. We tested this possibility by overexpressing Glut3
in Neuro2A and COS-7 cells. Overexpressed Glut3 translocates to
the plasma membrane in Neuro2A cells but not in COS-7 cells
(data not shown). We therefore measured the glycogen contents
of Neuro2A and COS-7 cells overexpressing Glut3, glycogen syn-
thase, or GFP (the latter two being controls). Overexpression of
Glut3 resulted in a significant increase in the cellular glycogen
content, but only in Neuro2A cells (Fig. 8E). However, knock-
down of laforin or malin caused a modest but significant increase
in the glycogen content, even in COS-7 cells that overexpressed
Glut3 (Fig. 8F). Taken together, our results suggest that laforin
and malin are critical regulators of glucose transport, that they
regulate this process by modulating the subcellular localization of
glucose transporters, and that the targeting of glucose transporters
to the plasma membrane increases cellular glycogen content.
We next wanted to check whether laforin and malin are in-
volved in glycogen degradation, since inhibition of this process
could also result in an increased glycogen level within the cell. To
test this possibility, COS-7 cells were transiently transfected with a
FIG7 The laforin-malin complex regulates glucose homeostasis. (A)Neuro2A cells were transfectedwith the indicated RNAi construct, and the difference in the
uptake of labeled glucose analogue 2-NBDG was measured and plotted. (B) COS-7 and Neuro2A cells were transiently transfected with the indicated RNAi
construct, and the level of endogenous glucose transporter Glut1 (COS-7) or Glut3 (Neuro2A) was evaluated in the whole-cell lysate (WCL) and in the plasma
membrane fraction (PMF). The levels of tubulin and transferrin receptor (TFR) served as loading controls. (C) Equal quantities (10g/lane) of protein samples
representing theWCL and PMF of Neuro2A cells shown in panel B were loaded in the same gel, resolved, and immunoblotted with antibodies for the indicated
membrane proteins to reveal the relative enrichment of membrane proteins in the PMF. (D) Immunoblot showing levels of Glut1 and Glut4 proteins in
whole-tissue lysate (WTL) and the PMFof soleus skeletalmuscle tissue of laforin knockoutmice (KO) and theirwild-type littermates (WT). Tubulin and caveolin
served as loading controls for WTL and PMF, respectively. (E) Neuro2A cells were transfected with a combination of constructs that code for GFP-Glut3 or the
WT or the mutants of laforin or malin, and the relative levels of Glut3 in the WCL or in the PMF were evaluated by immunoblotting. (F) Signal intensities
(Glut3/transferrin receptor ratio) of the immunoblot for the PMF shown in panel E (lower panel) were measured and plotted to reveal the fold difference. (G)
Bar diagram showing glucose uptake in Neuro2A cells transiently expressing the wild-type or the mutant form of laforin or malin as indicated. Values were
normalized over protein content and are presented as the fold change compared to pcDNA-transfected cells. , , and , P  0.05, 0.005, and 0.0005,
respectively.
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knockdown construct for laforin or malin or with the control
vector, and the cells were exposed to glucose-free medium at 36 h
posttransfection to degrade the glycogen reserve for the next 12 h.
As shown in Fig. 8G, the cellular glycogen content was lower in
cells that expressed the knockdown construct than cells that ex-
pressed the control vector, suggesting that laforin and malin are
not critical for glycogen degradation. Thus, the increase in glyco-
gen level observed in the absence of laforin or malin could be due
to increased glycogen synthesis via excessive glucose uptake and
not due to a defect in the glycogen degradation process.
DISCUSSION
Laforin andmalin are thought to function as nonredundant part-
ners in a functional complex (17), and several studies have shown
that this is indeed the case (14, 19, 39). Here we showed that
laforin andmalin, through an unknownmechanism but as nonre-
dundant partners, sense the intracellular glycogen level and nega-
tively regulate the cellular uptake of glucose. Partial knockdownof
either one resulted in excessive intracellular glycogen accumula-
tion, primarily via enhanced cellular glucose import.
The glycogen-dependent nuclear translocation observed for
laforin is similar to the that shown for muscle glycogen synthase
(MGS) (8); both of them translocate to the nucleus when glycogen
stores are depleted within the cell. Our results also demonstrated
that carbohydrate-binding ability is required for laforin to remain
in cytoplasm, and therefore the absence or a very low level of
glycogen is unable to retain laforin within the cytoplasm and
therefore it translocates to the nucleus. While the significance of
the nuclear translocation of laforin is not obvious to us, it should
be noted here that the nuclear MGS is thought to be involved in
transcriptional regulation (8) and that laforin, alongwithmalin, is
known to translocate to the nucleus upon thermal stress and to
regulate heat shock-induced transcription (39). Thus, laforin ap-
pears to have additional functions in the nucleus when cells are
under physiological stress, including the glucose deprivation con-
ditions tested in the present study.
Laforin is known to be degraded by malin via the ubiquitin-
proteasome pathway (20); however, the physiological significance
for this function is not well understood. We showed here that,
under physiological conditions, laforin’s stability was correlated
with the cellular glycogen content. Since loss of laforin results in
increased glucose uptake, it is reasonable to suggest that malin
promotes the degradation of laforin, probably via increases in the
cellular glucose level. This suggestion was supported by our ob-
servations that laforin displayed increased affinity toward malin
when cells were deprived of glucose, and there was a significant
decrease in the level of laforin when cells were starved of glucose,
which could be rescued when malin was partially knocked down
or when proteasomes were blocked. However, the laforin-malin
affinity and the malin-mediated degradation of laforin seem to be
regulated by at least by two factors: AMPK activity and cellular
ATP levels. AMPK is one of the critical enzymes involved in cel-
lular energy homeostasis and is known to be activated when cells
are deprived of energy source (22). Indeed, an earlier study (42)
FIG 8 Laforin and malin regulate glycogen synthesis but not its breakdown. (A) Bar diagram showing glycogen content in COS-7 and Neuro2A cells grown in
a medium with 25 mM glucose. (B) Bar diagram showing relative glycogen content in Neuro2A or COS-7 cells transiently transfected with the indicated RNAi
construct. The cellular glycogen level was estimated at 36 h posttransfection. (C) Neuro2A cells transfected with the indicated RNAi constructs were scored for
the presence of glycogen granules, as visualized with antiglycogen antibody, and plotted. (D) Bar diagram showing glycogen content of COS-7 cells transiently
transfected with the indicated RNAi construct and treated/not treated with cytochalasin B (CytoB). (E) Bar diagram showing the fold difference in the glycogen
content of COS-7 and Neuro2A cells transiently expressing GFP, glycogen synthase (GS), or Glut3, as indicated. (F) Bar diagram showing the fold change in the
glycogen content of COS-7 cells cotransfected with GFP, Glut3, and the RNAi construct. (G) COS-7 cells transiently transfected with the indicated RNAi
construct were transferred to glucose-free medium at 36 h posttransfection, and the cellular glycogen content was measured after 12 h of incubation and plotted
as the fold change. , , and , P 0.05, 0.005, and 0.0005, respectively.
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suggested that the laforin-malin interaction is mediated by
AMPK, although the functional significance of this role was not
explored.We showed here that active AMPK is required formalin
to promote the degradation of laforin when cells are deprived of
glucose. AMPK is less active when cells are not under metabolic
stress, and one of the triggers that activate AMPK is stimuli that
change the AMP:ATP ratio (22). Thus, there appears to be an
inverse correlation between AMPK activity and laforin level. In-
triguingly, active AMPK is unable to promote the degradation of
laforin when cellular ATP levels were high, suggesting that AMPK
is required but not sufficient for the degradation of laforin. These
data clearly indicate that the factor(s) that senses the cellular ATP
level could regulate the stability of laforin with the help of AMPK.
Similarly, that active AMPK (as during glucose deprivation) is
unable to prevent the nuclear translocation of laforin in cells that
are deprived of glycogen suggests the possible involvement of an
additional regulatory factor(s) that functions independently of
AMPK. Thus, ATP depletion is likely to activate AMPK as well as
an unknown factor(s), which together might promote the degra-
dation of laforin. The nuclear translocation or/and the degrada-
tion of laforin may help in the restoration of the energy level by
enhancing cellular glucose uptake within the cell. Taken together,
our data suggest that the laforin-malin complex is one of the crit-
ical players in cellular energy homeostasis.
Previous studies that investigated the possible role of laforin/
malin in glycogenmetabolism focused on the enzymes involved in
glycogen synthesis or its degradation (11, 14, 42, 44–46). Studies
from laforin- or malin-deficient animals have demonstrated that
none of the critical enzymes show any difference in their level or
activity (11, 44). We reasoned that the laforin-malin complex
could indirectly regulate glucose homeostasis, and we demon-
strated here that loss of laforin and malin results in excessive glu-
cose uptake. While the manuscript was in preparation, Vernia et
al. (47) reported excessive glucose uptake in the tissues of laforin-
deficient mice, suggesting that loss of laforin (and possibly malin)
might have similar effects at both tissue and cellular levels. We
have shown here that loss of laforin or malin increases the abun-
dance of glucose transporters in the plasmamembrane and hence
excessive glucose uptake. Similar observations were also made in
the muscle tissue of laforin-deficient mice. Intriguingly, laforin
and malin appear to regulate the translocation of the glucose
transporters Glut1, Glut3, and Glut4 to the plasma membrane,
although their cellular level remains unchanged. Glut1 and Glut3
represent the twomajor insulin-independent glucose transporters
found in nonneuronal and neuronal tissues, respectively, and
Glut4 is exclusively expressed in striatedmuscle (4). In this regard
it is interesting that the plasma insulin level did not change in
laforin-deficient mice (47), and we did not use insulin in our glu-
cose uptake assays. Therefore, the laforin-malin complex possibly
regulates glucose homeostasis via an insulin-independent glucose
uptake mechanism, a constitutive process that accounts for most
of the basal glucose uptake in tissues (4). Glucose transporters are
found both at cytoplasmic vesicles and at the plasma membrane
(4, 28). Under conditions of a glucose requirement, vesicles target
the glucose transporters to the plasma membrane via exocytosis,
and when the glucose demand is met, most of the transporters are
shunted back to the cytoplasmic vesicle via endocytosis (28).What
we have shown here is that coexpression of laforin or malin is able
to restrict Glut3 in the cytoplasmic vesicles. While our observa-
tions are strong enough to suggest that the laforin-malin complex
regulates the subcellular trafficking of glucose transporters, the
specific process by which laforin and malin are able to modulate
the vesicular trafficking was not addressed in the present study.
Clearly, further studies are required to elucidate this mechanism.
In summary, we have shown that the laforin-malin complex
regulates glucose uptake and not the degradative process of cellu-
lar glycogen. Thus, excessive substrate (cellular glucose level) ap-
pears to be the trigger for the abnormally high levels of glycogen
seen in LD. Thus, laforin/malin deficiency would result in an ab-
normal increase in cellular glycogen that is less branched and hy-
perphosphoryled, leading to the genesis of Lafora bodies. Our
study indicates that factors that regulate cellular glucose uptake
could be potential therapeutic targets for the treatment of LD.
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